CTM-N2D-001
Various Solid Tumors
Phase 1Active
Key Facts
About CytoMed Therapeutics
CytoMed Therapeutics is a clinical-stage biotech focused on translating innovative allogeneic cell therapies into treatments for a broad spectrum of cancers. Its mission is to overcome the manufacturing complexity, cost, and delay associated with autologous cell therapies by leveraging donor-derived gamma-delta T cells and NK cells. The company has established a dual-platform strategy, combining its proprietary cell expansion techniques with CAR engineering, and is progressing multiple candidates towards clinical validation. As a public entity, CytoMed is positioned within Singapore's strong biomedical ecosystem to advance its next-generation immunotherapy pipeline.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Guardant Infinity Biomarker Discovery | Guardant Health | Development/Commercial |
| Cytotoxic Oncology Generic | MSN Laboratories | Pre‑clinical |
| APCEDEN® | APAC Biotech | Approved |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| 177Lu‑BetaBart (RV‑01) | AtomVie Global Radiopharma | Phase 1/2a |
| BeiGene Oncology Portfolio | EVA Pharma | Phase 2/3 |
| Bevacizumab Biosimilar | Bio Usawa Biotechnology | Preclinical |